Juno Therapeutics (NASDAQ:JUNO) was downgraded by equities research analysts at Wedbush from an “outperform” rating to a “neutral” rating in a research report issued on Wednesday, The Fly reports.
Several other research analysts also recently issued reports on JUNO. Morgan Stanley reissued an “equal weight” rating and set a $43.00 price objective (up from $27.00) on shares of Juno Therapeutics in a research report on Friday, October 6th. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $44.00 target price on shares of Juno Therapeutics in a report on Friday, October 6th. Maxim Group reaffirmed a “buy” rating and issued a $56.00 target price (up previously from $34.00) on shares of Juno Therapeutics in a report on Monday, October 9th. Cowen reaffirmed a “buy” rating and issued a $49.00 target price on shares of Juno Therapeutics in a report on Friday, October 27th. Finally, Citigroup reaffirmed a “buy” rating and issued a $59.00 target price on shares of Juno Therapeutics in a report on Tuesday, October 31st. Three analysts have rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the stock. Juno Therapeutics currently has an average rating of “Hold” and an average price target of $47.26.
Shares of Juno Therapeutics (JUNO) traded up $23.65 during trading on Wednesday, reaching $69.25. 22,180,382 shares of the company’s stock traded hands, compared to its average volume of 2,440,000. Juno Therapeutics has a 52 week low of $18.90 and a 52 week high of $70.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77. The stock has a market cap of $7,910.00, a P/E ratio of -20.43 and a beta of 2.32.
In related news, EVP Robert Azelby sold 1,816 shares of the firm’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $44.96, for a total value of $81,647.36. Following the completion of the sale, the executive vice president now owns 70,832 shares in the company, valued at $3,184,606.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard Klausner sold 36,000 shares of the firm’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $44.76, for a total transaction of $1,611,360.00. Following the completion of the sale, the director now owns 744,392 shares of the company’s stock, valued at approximately $33,318,985.92. The disclosure for this sale can be found here. Insiders sold 65,956 shares of company stock valued at $3,064,378 in the last quarter. Company insiders own 15.08% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in JUNO. Capital International Investors acquired a new stake in shares of Juno Therapeutics in the third quarter valued at about $256,339,000. Redmile Group LLC acquired a new position in Juno Therapeutics during the second quarter worth about $66,344,000. Jennison Associates LLC raised its position in Juno Therapeutics by 162.0% during the third quarter. Jennison Associates LLC now owns 1,988,708 shares of the biopharmaceutical company’s stock worth $89,213,000 after acquiring an additional 1,229,622 shares during the last quarter. Orbimed Advisors LLC raised its position in Juno Therapeutics by 123.1% during the third quarter. Orbimed Advisors LLC now owns 2,041,608 shares of the biopharmaceutical company’s stock worth $91,587,000 after acquiring an additional 1,126,400 shares during the last quarter. Finally, Capital Guardian Trust Co. acquired a new position in Juno Therapeutics during the third quarter worth about $37,400,000. Hedge funds and other institutional investors own 69.94% of the company’s stock.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
